奈韦拉平治疗获得性免疫缺陷综合征导致肝损伤的危险因素分析

刘佩; 高世成

doi:10.3969/j.issn.1001-5256.2016.07.035

奈韦拉平治疗获得性免疫缺陷综合征导致肝损伤的危险因素分析

DOI: 10.3969/j.issn.1001-5256.2016.07.035

刘佩,
高世成

武汉大学中南医院感染科

基金项目:

湖北省自然科学基金(湖北省科技厅)(2011CDB529)；

详细信息

中图分类号: R575;R512.91
计量
- 文章访问数: 1988
- HTML全文浏览量: 30
- PDF下载量: 444
- 被引次数: 0
出版历程
- 出版日期: 2016-07-20

Risk factors for liver injury in patients with acquired immunodeficiency syndrome treated with nevirapine

Research funding:

摘要

摘要:
目的分析获得性免疫缺陷综合征患者使用包含奈韦拉平（NVP）方案进行联合抗反转录病毒治疗（c-ART）引起超敏反应肝损伤的相关危险因素。方法收集2008年6月-2015年10月武汉大学中南医院接受包含NVP联合治疗方案的患者临床资料及血液标本共132例,采用PCR-SSP技术检测人类白细胞抗原（HLA）DRB1及HLA-Cw基因型。开始c-ART治疗6周内出现NVP超敏反应相关肝损伤者列为肝损伤组（n=41）,未发生肝损伤者为对照组（n=91）,分析NVP超敏反应引起肝损伤的相关危险因素。计量资料组间比较采用t检验;计数资料组间比较采用χ2检验。采用单因素Logistic回归法分析NVP超敏反应相关肝损伤的危险因素,将P<0.10的单因素分析变量纳入多因素Logistic回归模型进行逐步回归分析。用Spearman相关系数分析发生超敏反应相关肝损患者中CD4细胞数与ALT值的相关性。结果多因素Logistic回归分析显示男性[P=0.002,比值比（OR）=12.297,95%可信区间（95%CI）:2.46761.300]、基线CD4细...
- 肝疾病 /
- 奈韦拉平 /
- 超敏反应 /
- 危险因素
Abstract:
Objective To investigate the risk factors for hypersensitivity- associated liver injury induced by the combined antiretroviral therapy( c- ART) including nevirapine( NVP) in patients with acquired immunodeficiency syndrome. Methods The clinical data and blood samples of 132 patients who received the combined therapy including NVP in Zhongnan Hospital of Wuhan University from June 2008 to October 2015 were collected,and PCR- SSP was used to determine the genotypes of human leukocyte antigen( HLA) DRB1 and HLA-Cw. The patients who experienced hypersensitivity- associated liver injury induced by NVP within 6 weeks of c- ART were enrolled in the liver injury group( 41 patients),and those who did not experience liver injury were enrolled in the control group( 91 patients). The risk factors for liver injury induced by NVP hypersensitivity were analyzed. The t- test was used for comparison of continuous data between groups; the chi- square test was used for comparison of categorical data between groups. The univariate logistic regression method was used to analyze the risk factors for liver injury associated with NVP hypersensitivity,and the variables with P < 0. 10 were included in the multivariate logistic regression model to perform stepwise regression analysis. The Spearman correlation coefficient was used to analyze the correlation between the number of CD4 cells and alanine aminotransferase( ALT) level in patients experiencing hypersensitivity- associated liver injury. Results The results of the multivariate logistic regression analysis showed that male sex( OR = 12. 297,95% CI: 2. 467- 61. 300,P = 0. 002),a high CD4 cell count at baseline( OR = 1. 010,95% CI: 1. 001- 1. 018,P = 0. 022),HCV co- infection( OR = 10. 598,95%CI: 1. 411- 79. 613,P = 0. 022),and a HLA- Cw*03 carrier( OR = 34. 119,95% CI: 5. 543- 210. 023,P < 0. 001) were risk factors for liver injury associated with NVP hypersensitivity. In the patients with HCV co- infection or a high CD4 cell count( ≥200 / μl) or carrying HLA- Cw*03 allele,male patients had a significantly higher incidence rate of liver injury than female patients( 63. 9% vs 11. 6%,χ2= 23. 390,P < 0. 001). Baseline CD4 cell count was positively correlated with ALT level( r = 0. 583,P < 0. 001). Conclusion Male patients infected with human immunodeficiency virus who are co- infected with HCV and have a high CD4 cell count at baseline should avoid using NVP.The value of HLA- Cw*03 gene screening in predicting hepatotoxicity associated with NVP hypersensitivity awaits further investigation.
- liver diseases /
- nevirapine /
- hypersensitirity /
- risk factors

HTML全文

参考文献(19)

[1]HAO LZ,ZHU XY,YANG XG,et al.Survival analysis of AIDSpatients receiving antiretroviral therapy in Globe Fund supported counties of Shandong[J].Chin J AIDS STD,2014,20(9):634-637.(in Chinese)郝连正,朱晓艳,杨兴光,等.山东省全球基金项目县艾滋病ART病人的生存状况[J].中国艾滋病性病,2014,20(9):634-637.

[2] ROSSI SM,MALUF EC,CARVALHO DS,et al.Impact of antiretroviral therapy under different treatment regimens[J].Rev Panam Salud Publica,2012,32(2):117-123.

[3] AIDS Group,Society of Infectious Diseases,Chinese Medical Association.Guideline of diagnosis and treatment for AIDS[J].Chin JClin Infect Dis,2011,4(6):321-330.(in Chinese)中华医学会感染病学分会艾滋病学组.艾滋病诊疗指南(2011版)[J].中华临床感染病杂志,2011,4(6):321-330.

[4]ZI M,CAI HD,LI XX.A literature review of adverse effects of nevirapine[J].Chin J Pharmacoepidemiol,2007,16(5):284-287.(in Chinese)訾梅,蔡皓东,李祥霞.奈韦拉平不良反应文献分析[J].药物流行病学杂志,2007,16(5):284-287.

[5]FAN WS,LI W,LIU Y,et al.Correlation between the adverse effects associated with the use of Nevirapine and CD4+lymphocyte count[J].China Foreign Med Treatment,2014,10:34-35.(in Chinese)范文穗,李巍,刘艳,等.奈韦拉平抗病毒治疗药物不良反应与CD4+淋巴细胞计数的关系[J].中外医疗,2014,10:34-35.

[6] GAO S,GUI XE,LIANG K,et al.HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients[J].AIDS Res Hum Retroviruses,2012,28(6):540-543.

[7]GAO SC,GUI XE,DENG LP,et al.Nevirapine related hepatotoxicity:the prevalence and risk factors in a cohort of ART nave Han Chinese with AIDS[J].Chin J Hepatol,2010,18(9):689-693.(in Chinese)高世成,桂希恩,邓莉平,等.奈韦拉平相关肝毒性的发病率及危险因素[J].中华肝脏病杂志,2010,18(9):689-693.

[8]The National Free Antiretroviral Treatment Manual Drafting Group.The national free antiretroviral treatment manual[M].Beijing:People's Medical Publishing House,2012:16-20.(in Chinese)《国家免费艾滋病抗病毒药物治疗手册》编写组.国家免费艾滋病抗病毒药物治疗手册[M].北京:人民卫生出版社,2012:16-20.

[9]Drug-induced Liver Disease Study Group,Chinese Society of Hepatology,Chinese Medical Association.Guidelines for the management of drug-induced liver injury[J].J Clin Hepatol,2015,31(11):1752-1769.(in Chinese)中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志,2015,31(11):1752-1769.

[10]STERN JO,ROBINSON PA,LOVE J,et al.A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients[J].J Acquir Immune Defic Syndr,2003,34(Suppl1):s21-s33.

[11] FDA advisory on nevirapine[J].AIDS Treat News,2005,409:7.

[12]LI WJ,DAI Y,HAN Y,et al.Safety study of 52-week highly active antiretroviral therapy in 198 HIV/AIDS Chinese patients[J].Natl Med J China,2011,91(19):1318-1322.(in Chinese)李文娟,戴懿,韩扬,等.198例中国HIV/AIDS患者接受52周HAART的安全性评价[J].中华医学杂志,2011,91(19):1318-1322.

[13] DICKINSON L,CHAPONDA M,CARR DF,et al.Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi[J].Antimicrob Agents Chemother,2014,58(2):706-712.

[14]LI TS.Adverse events of nevirapine for HIV/AIDS treatment[J].Chin J Viral Dis,2011,1(6):405-407.(in Chinese)李太生.奈韦拉平治疗相关不良反应的研究进展[J].中国病毒病杂志,2011,1(6):405-407.

[15]ZHANG XL.Epidemiological characteristics and clinical features on HIV co-infection with HBV and/or HCV[D].Kunming:Kunming Med Univ,2013.(in Chinese)张小丽.HIV/AIDS合并HBV/HCV感染的流行病学特征及临床特点[D].昆明:昆明医科大学,2013.

[16]DENG LP.A clinical study about human immunodeficiency virus and hepatitis C virus coinfection[D].Wuhan:Wuhan Univ,2012.(in Chinese)邓莉平.人类免疫缺陷病毒与丙型肝炎病毒合并感染的临床研究[D].武汉:武汉大学,2012.

[17]GAO S,GUI XE,DENG L,et al.Antiretroviral therapy hepatotoxicity:Prevalence,risk factors,and clinical characteristics in a cohort of Han Chinese[J].Hepatol Res,2010,40(4):287-294.

[18]LITTERA R,CARCASSI C,MASALA A,et al.HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients[J].AIDS,2006,20(12):1621-1626.

[19]GATANAGA H,YAZAKI H,TANUMA J,et al.HLA-Cw8 primarily associated with hypersensitivity to nevirapine[J].AIDS,2007,21(2):264-265.

施引文献

资源附件(0)

访问统计